CRISPR Therapeutics AG
CRSP
$43.83
-$1.70-3.73%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -82.26% | -- | -99.26% | -99.50% | 3,353,333.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -82.26% | -- | -99.26% | -99.50% | 3,353,333.33% |
| Cost of Revenue | -28.65% | -18.23% | -9.50% | -13.36% | 4.32% |
| Gross Profit | -153.99% | 18.76% | -72.96% | -191.11% | 177.97% |
| SG&A Expenses | 9.98% | -4.77% | 2.36% | -19.71% | -22.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.81% | -16.37% | -8.14% | -14.22% | 0.06% |
| Operating Income | -192.82% | 16.83% | -58.85% | -118.01% | 152.90% |
| Income Before Tax | -140.87% | 23.87% | -62.88% | -123.92% | 174.62% |
| Income Tax Expenses | 200.43% | 112.62% | 39.44% | -45.15% | 102.46% |
| Earnings from Continuing Operations | -141.76% | 23.37% | -62.60% | -119.71% | 180.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -141.76% | 23.37% | -62.60% | -119.71% | 180.80% |
| EBIT | -192.82% | 16.83% | -58.85% | -118.01% | 152.90% |
| EBITDA | -180.21% | 17.33% | -62.21% | -128.40% | 159.26% |
| EPS Basic | -138.94% | 28.60% | -51.44% | -111.33% | 179.43% |
| Normalized Basic EPS | -138.10% | 29.07% | -51.71% | -115.35% | 173.36% |
| EPS Diluted | -139.88% | 28.48% | -51.59% | -112.01% | 177.56% |
| Normalized Diluted EPS | -138.89% | 29.07% | -51.71% | -115.35% | 171.87% |
| Average Basic Shares Outstanding | 7.25% | 7.33% | 7.37% | 3.96% | 1.73% |
| Average Diluted Shares Outstanding | 5.09% | 7.33% | 7.37% | 3.96% | 3.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
